-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39

Benzinga·08/12/2026 09:37:18
Listen to the news
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $28 to $39.